Literature DB >> 15913509

Management of Perianal Crohn's Disease.

Benjamin Person1, Steven D Wexner.   

Abstract

Perianal manifestations of Crohn's disease usually coexist with active inflammation of other primary sites of the disease. Although treatment of active proximal disease may sometimes alleviate perianal symptoms, it is reasonable to separately treat symptomatic perianal disease. The diversity of perianal manifestations in Crohn's disease mandates a tailored, individualized approach in every case. Medical therapy is the best treatment option for hemorrhoids and anal fissures. The medical management of patients with perianal Crohn's disease includes the use of systemic antibiotics, immunosuppressive agents, and infliximab. Infliximab is now recognized as a very efficacious agent for treating fistulizing Crohn's disease, including perianal fistulae. It may also reduce the need for surgical intervention in specific cases. Abscesses and fistulae are treated by control of sepsis, resolution of inflammation and optimal preservation of continence, and quality of life. Abscesses require surgical drainage that may need to be prolonged to achieve complete healing. Fistulae may be treated medically, especially in cases of concurrent proctitis. Refractory fistulae may require surgical treatment including an occasional need for fecal diversion or proctectomy. The role of new treatment options such as natalizumab and CDP571 is evolving and requires further investigation.

Entities:  

Year:  2005        PMID: 15913509     DOI: 10.1007/s11938-005-0012-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  76 in total

1.  Symposium. Crohn's disease: anal lesions.

Authors:  H E Lockhart-Mummery
Journal:  Dis Colon Rectum       Date:  1975-04       Impact factor: 4.585

Review 2.  Fibrin glue in the management of anal fistulae.

Authors:  T M Hammond; M F Grahn; P J Lunniss
Journal:  Colorectal Dis       Date:  2004-09       Impact factor: 3.788

3.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors:  W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal:  Lancet       Date:  1997-02-22       Impact factor: 79.321

4.  Localized Chronic Ulcerative Ileitis.

Authors:  A D Bissell
Journal:  Ann Surg       Date:  1934-06       Impact factor: 12.969

5.  Surgical treatment of anorectal fistula in patients with Crohn's disease.

Authors:  D H Levien; J Surrell; W P Mazier
Journal:  Surg Gynecol Obstet       Date:  1989-08

6.  Topical diltiazem ointment in the treatment of chronic anal fissure.

Authors:  J S Knight; M Birks; R Farouk
Journal:  Br J Surg       Date:  2001-04       Impact factor: 6.939

7.  Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.

Authors:  L J Egan; W J Sandborn; W J Tremaine
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

8.  Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.

Authors:  H Kotanagi; M Ito; K Koyama; M Chiba
Journal:  J Gastroenterol       Date:  1998-08       Impact factor: 7.527

9.  Surgical pathology and management of anorectal Crohn's disease.

Authors:  L E Hughes
Journal:  J R Soc Med       Date:  1978-09       Impact factor: 5.344

Review 10.  Probiotics and the management of inflammatory bowel disease.

Authors:  Richard N Fedorak; Karen L Madsen
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more
  2 in total

1.  Perianal Crohn's disease.

Authors:  Bashar Safar; Dana Sands
Journal:  Clin Colon Rectal Surg       Date:  2007-11

Review 2.  Idiopathic fistula-in-ano.

Authors:  Sherief Shawki; Steven D Wexner
Journal:  World J Gastroenterol       Date:  2011-07-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.